ArticleNature communications2023
Plasma proteomic profiles predict individual future health risk.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.
- A systematic review of the neuroprotective role and biomarker potential of GDF15 in neurodegeneration.Frontiers in immunology · 2024Pooled it
- Glycemic status-dependent proteomic signatures of biological aging for health risk prediction.GeroScience · 2026Article
- Explainable Plasma Proteomics-Based Machine Learning for Osteoporosis Diagnosis, Prognosis, and Protein Biomarker Discovery in the UK Biobank.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Plasma Proteomic Profiles Predict Subsequent Obstructive Sleep Apnea Diagnosis in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Article
- ProLM: a plasma proteomics pretrained model for the general population.Nature communications · 2026Article
- Clinical validation of PEA-driven Olink proteomic discovery: INPP1 and ARHGAP25 serum biomarkers improve early breast cancer diagnosis.Translational oncology · 2026Article
- Functional, molecular, and digital measurements of biological age.The Journal of clinical investigation · 2026Review
- UK Biobank at 20 - a growing, global resource for dementia research.Nature reviews. Neurology · 2026Review
- Adiposity and cancer: epidemiology, mechanisms and future perspectives.Nature metabolism · 2026Review
- A lipidomics roadmap: from basic research to societal challenges.Nature communications · 2026Review
- Mapping the GDF15 arm of the integrated stress response in human cells and tissues.Communications biology · 2026Article
- Enhanced Prediction of Peripheral Artery Disease Using Plasma Proteomics Among Individuals Without Diabetes.Journal of the American Heart Association · 2026Article
- A cumulative-morbidity plasma proteomic architecture of critical-illness susceptibility: a UK biobank proteome-wide study of critical-care exposure, in-hospital death, and sex-specific signals.Journal of intensive care · 2026Article
- Plasma Multiomics Links Early-Life Adversity to Disease and Cardiometabolic Health: A Population-Based Cohort Study.Journal of the American Heart Association · 2026Article
- Associations between plasma proteins and psychological wellbeing: evidence from over 20 years of the English Longitudinal Study of Ageing.Molecular psychiatry · 2026Article
- Brain Aging Mediating Heart Imaging-Derived Phenotypes and Mental and Nervous System Disorders.Aging cell · 2026Article
- Interpretable neural network for risk stratification and drug target discovery based on PBMC transcriptomes.iScience · 2026Article
- Article
- Neural vulnerability to stress in adolescents: a longitudinal study using polyconnectomic scoring of depression risk.BMC medicine · 2026Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Developing a single-domain assay to identify individuals at high risk of future events is a priority for multi-disease and mortality prevention. By training a neural network, we developed a disease/mortality-specific proteomic risk score (ProRS) based on 1461 Olink plasma proteins measured in 52,006 UK Biobank participants. This integrative score markedly stratified the risk for 45 common conditions, including infectious, hematological, endocrine, psychiatric, neurological, sensory, circulatory, respiratory, digestive, cutaneous, musculoskeletal, and genitourinary diseases, cancers, and mortality. The discriminations witnessed high accuracies achieved by ProRS for 10 endpoints (e.g., cancer, dementia, and death), with C-indexes exceeding 0.80. Notably, ProRS produced much better or equivalent predictive performance than established clinical indicators for almost all endpoints. Incorporating clinical predictors with ProRS enhanced predictive power for most endpoints, but this combination only exhibited limited improvement when compared to ProRS alone. Some proteins, e.g., GDF15, exhibited important discriminative values for various diseases. We also showed that the good discriminative performance observed could be largely translated into practical clinical utility. Taken together, proteomic profiles may serve as a replacement for complex laboratory tests or clinical measures to refine the comprehensive risk assessments of multiple diseases and mortalities simultaneously. Our models were internally validated in the UK Biobank; thus, further independent external validations are necessary to confirm our findings before application in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.